Skip to main content
. Author manuscript; available in PMC: 2022 May 1.
Published in final edited form as: Leuk Lymphoma. 2020 Dec 28;62(5):1187–1194. doi: 10.1080/10428194.2020.1861270

Table 2.

Dose levels and dose-limiting toxicities

Dose Level Bortezomib (mg/m2) D1,4,8,11 IV Push Belinostat (mg/m2) D1-5, 8-12 IV Number of Patients Treated/Number of Patients DLT Evaluable DLT Event Median Number of Cycles (Range)
1 1.0 500 6/3 1.5 (1-4)
2 1.3 500 6/4 1.5 (1-4)
3 1.3 650 4/3 2 (1-2)
4 1.3 850 3/3 6 (2-10)
5* 1.3 1000 9/6 3 (1-14)
6 1.3 1200 7/6 Gr3 QTc prolongation (2 patients) 2 (1-32)
7 1.3 1400 3/2 Gr3 QTc prolongation (2 patients) 2 (1-8)
*

Maximum tolerated dose (MTD).